Anbio Biotechnology Class A Ordinary Shares (NNNN) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
494.75
—
5yr avg: N/A
P/FCF
616.05
—
5yr avg: N/A
P/B Ratio
71.83
—
5yr avg: N/A
ROE
↓
14.8%
↑-78% vs avg
5yr avg: 66.0%
30Y Low15%·High133%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NNNN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Anbio Biotechnology Class A Ordinary Shares trades at 521.4x earnings, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 2250%. On a free-cash-flow basis, the stock trades at 616.1x P/FCF.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $1.3B | — | — | — | — |
| Enterprise Value | $1.3B | — | — | — | — |
| P/E Ratio → | 521.43 | — | — | — | — |
| P/S Ratio | 156.58 | — | — | — | — |
| P/B Ratio | 71.83 | — | — | — | — |
| P/FCF | 616.05 | — | — | — | — |
| P/OCF | 616.05 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NNNN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Anbio Biotechnology Class A Ordinary Shares's enterprise value stands at 494.7x EBITDA. The Healthcare sector median is 14.0x, placing the stock at a 3429% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | 494.75 | — | — | — | — |
| EV / EBIT | 636.41 | — | — | — | — |
| EV / FCF | — | — | — | — | — |
NNNN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Anbio Biotechnology Class A Ordinary Shares earns an operating margin of 24.4%. Operating margins have compressed from 43.3% to 24.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 14.8% is modest. ROIC of 28.3% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 71.9% | 71.9% | 50.1% | 53.4% | 57.4% |
| Operating Margin | 24.4% | 24.4% | 29.2% | 43.3% | 55.5% |
| Net Profit Margin | 29.0% | 29.0% | 33.6% | 42.5% | 57.3% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | 14.8% | 14.8% | 16.5% | 132.7% | 100.0% |
| ROA | 13.7% | 13.7% | 15.1% | 106.1% | 51.6% |
| ROIC | 28.3% | 28.3% | 27.8% | 402.5% | — |
| ROCE | 12.5% | 12.5% | 14.3% | 135.2% | 96.8% |
NNNN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $12M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.68 | -0.65 | -0.57 | -1.65 |
| Net Debt / EBITDA | -4.58 | -4.58 | -4.91 | -0.70 | -1.65 |
| Debt / FCF | — | -5.65 | -10.78 | -1.60 | -1.00 |
| Interest Coverage | — | — | — | 1274.61 | — |
Net cash position: cash ($12M) exceeds total debt ($0)
NNNN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Anbio Biotechnology Class A Ordinary Shares's current ratio of 10.71x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.88x to 10.71x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 10.71 | 10.71 | 15.86 | 9.88 | 2.07 |
| Quick Ratio | 10.71 | 10.71 | 15.86 | 9.63 | 2.07 |
| Cash Ratio | 6.80 | 6.80 | 9.76 | 6.14 | 1.76 |
| Asset Turnover | — | 0.43 | 0.42 | 1.69 | 0.90 |
| Inventory Turnover | 31.03 | — | — | 31.03 | — |
| Days Sales Outstanding | — | 47.48 | 102.50 | 0.06 | 59.14 |
NNNN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Anbio Biotechnology Class A Ordinary Shares does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | 0.2% | — | — | — | — |
| FCF Yield | 0.2% | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — |
| Shares Outstanding | — | $42M | $188M | $144M | $100M |
Peer Comparison
Compare NNNN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NNNNYou | $1B | 521.4 | 494.7 | 616.1 | 71.9% | 24.4% | 14.8% | 28.3% | — |
 CLOV | $1B | -15.4 | — | — | 103.6% | -4.4% | -26.3% | -34.0% | — |
 ACHC | $2B | -2.1 | 8.4 | — | 17.6% | 11.7% | -41.4% | 5.9% | 4.6 |
 QDEL | $794M | -0.7 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 CHEK | $12M | -0.5 | — | — | — | — | -226.2% | -287.7% | — |
 IDXX | $45B | 43.0 | 31.2 | 42.6 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 BIO | $7B | 9.2 | 16.7 | 18.5 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 NEOG | $2B | -1.8 | 20.7 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 ALGN | $12B | 29.9 | 14.0 | 24.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 TMO | $173B | 26.3 | 18.8 | 27.6 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See NNNN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NNNN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NNNN vs CLOV
Side-by-side business, growth, and profitability comparison vs Clover Health Investments, Corp..
Start ComparisonNNNN — Frequently Asked Questions
Quick answers to the most common questions about buying NNNN stock.
What is Anbio Biotechnology Class A Ordinary Shares's P/E ratio?
Anbio Biotechnology Class A Ordinary Shares's current P/E ratio is 521.4x. This places it at the 50th percentile of its historical range.
What is Anbio Biotechnology Class A Ordinary Shares's EV/EBITDA?
Anbio Biotechnology Class A Ordinary Shares's current EV/EBITDA is 494.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Anbio Biotechnology Class A Ordinary Shares's ROE?
Anbio Biotechnology Class A Ordinary Shares's return on equity (ROE) is 14.8%. The historical average is 66.0%.
Is NNNN stock overvalued?
Based on historical data, Anbio Biotechnology Class A Ordinary Shares is trading at a P/E of 521.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Anbio Biotechnology Class A Ordinary Shares's profit margins?
Anbio Biotechnology Class A Ordinary Shares has 71.9% gross margin and 24.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.